Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation

IMPORTANCE: Patients with nonvalvular atrial fibrillation at risk of stroke should receive oral anticoagulants (OAC). However, approximately 1 in 8 patients in the Global Anticoagulant Registry in the Field (GARFIELD-AF) registry are treated with antiplatelet (AP) drugs in addition to OAC, with or w...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JAMA Netw Open
Asıl Yazarlar: Fox, Keith A. A., Velentgas, Priscilla, Camm, A. John, Bassand, Jean-Pierre, Fitzmaurice, David A., Gersh, Bernard J., Goldhaber, Samuel Z., Goto, Shinya, Haas, Sylvia, Misselwitz, Frank, Pieper, Karen S., Turpie, Alexander G. G., Verheugt, Freek W. A., Dabrowski, Elizabeth, Luo, Kaiyi, Gibbs, Liza, Kakkar, Ajay K.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Medical Association 2020
Konular:
Original Investigation
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7137686/
https://ncbi.nlm.nih.gov/pubmed/32101311
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2020.0107
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller